Loading clinical trials...
Loading clinical trials...
Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: An Open-Label, Non- Inferiority, Randomized, Controlled Trial
Conditions
Interventions
Omadacycline Pill
Standard of Care
Locations
1
United States
The Lundquist Institute For Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California, United States
Start Date
May 9, 2023
Primary Completion Date
February 1, 2026
Completion Date
June 1, 2026
Last Updated
January 14, 2026
NCT07406893
NCT05169229
NCT06827496
NCT06062251
NCT06464770
NCT05927311
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions